STAT3 and neoplasm: Just as an example, in renal and bladder cancers, the PD-1 blockade strategy had no effect, but the combined treatment of anti-PD-1 with an original antisense oligonucleotide (ASO) for myeloid cell selective STAT3 knockdown (CpG-STAT3ASO) worked very well by reprogramming M2-like macrophages and promoting M1-like anti-tumor immunity in the TME, resulting in increased tumor growth control [88].